Drugs that contain Sorafenib Tosylate
1. Drug name - NEXAVAR
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8877933 | BAYER HLTHCARE | Thermodynamically stable form of a tosylate salt |
Dec, 2027
(5 years from now) | |
| CN101065360B | BAYER HLTHCARE | Bay43-9006 Toluene Sulfonate Of Thermodynamically Stable Form |
Sep, 2025
(2 years from now) | |
| CN101065360A | BAYER HLTHCARE | Thermodynamics Stabilizing Form Of Bay43-9006 Toluenesulfonate |
Sep, 2025
(2 years from now) | |
| EP1797038B1 | BAYER HLTHCARE | Thermodynamically Stable Form Of Bay 43-9006 Tosylate |
Sep, 2025
(2 years from now) | |
| EP1797038A1 | BAYER HLTHCARE | Thermodynamically Stable Form Of Bay 43-9006 Tosylate |
Sep, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8618141 | BAYER HLTHCARE | Aryl ureas with angiogenesis inhibiting activity |
Feb, 2023
(4 months from now) | |
| US9737488 | BAYER HLTHCARE | Pharmaceutical composition for the treatment of cancer |
Sep, 2028
(5 years from now) | |
Treatment: Treatment of advanced renal cell carcinoma; Treatment of locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment; treatment of advanced renal cell carcinoma; treatment of unresectable hepatocellular carcinoma
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 200MG BASE | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.